These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26635117)

  • 21. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
    Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
    Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
    Ju LX; Zhou CC; Tang L; Zhao YM; Yang XJ; Su B; Meng SY; Li W; Yan LH; Ding YM
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 May; 33(5):354-8. PubMed ID: 20646614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanism of m
    Liu S; Li Q; Li G; Zhang Q; Zhuo L; Han X; Zhang M; Chen X; Pan T; Yan L; Jin T; Wang J; Lv Q; Sui X; Xie T
    Cell Death Dis; 2020 Nov; 11(11):969. PubMed ID: 33177491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
    Bai XY; Zhang XC; Yang SQ; An SJ; Chen ZH; Su J; Xie Z; Gou LY; Wu YL
    PLoS One; 2016; 11(3):e0149370. PubMed ID: 26943330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
    Ju L; Zhou C; Li W; Yan L
    J Cell Biochem; 2010 Dec; 111(6):1565-74. PubMed ID: 21053345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
    Deng QF; Su B; Zhao YM; Zhou CC
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):813-6. PubMed ID: 19173824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.
    Feng C; Liu X; Li X; Guo F; Huang C; Qin Q; Wang Y
    Oncol Rep; 2016 Jun; 35(6):3460-70. PubMed ID: 27109760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
    Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
    Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Afatinib Decreases P-Glycoprotein Expression to Promote Adriamycin Toxicity of A549T Cells.
    Zhang Y; Wang CY; Duan YJ; Huo XK; Meng Q; Liu ZH; Sun HJ; Ma XD; Liu KX
    J Cell Biochem; 2018 Jan; 119(1):414-423. PubMed ID: 28590019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
    Ohtsuka K; Ohnishi H; Morii T; Fujiwara M; Kishino T; Ogura W; Chiba M; Matsushima S; Goya T; Watanabe T
    J Thorac Oncol; 2010 Nov; 5(11):1726-33. PubMed ID: 20975373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
    Yang SH; Lin HY; Chang VH; Chen CC; Liu YR; Wang J; Zhang K; Jiang X; Yen Y
    Oncotarget; 2015 Sep; 6(27):23857-73. PubMed ID: 26160843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Honokiol exhibits enhanced antitumor effects with chloroquine by inducing cell death and inhibiting autophagy in human non-small cell lung cancer cells.
    Lv X; Liu F; Shang Y; Chen SZ
    Oncol Rep; 2015 Sep; 34(3):1289-300. PubMed ID: 26136140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer.
    Liu W; Ning J; Li C; Hu J; Meng Q; Lu H; Cai L
    Tumour Biol; 2016 May; 37(5):6331-6. PubMed ID: 26628299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
    Shen H; Yuan Y; Sun J; Gao W; Shu YQ
    Biomed Pharmacother; 2010 Feb; 64(2):88-92. PubMed ID: 20005069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.